Sergio Traversa's most recent trade in Relmada Therapeutics Inc was a trade of 129,455 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on Aug. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.67 per share. | 26 Aug 2025 | 129,455 | 944,024 (6%) | 0% | 0.7 | 86,735 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.62 per share. | 26 Aug 2025 | 80,545 | 814,569 (5%) | 0% | 0.6 | 49,938 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.74 per share. | 26 Aug 2025 | 55,976 | 1,000,000 (6%) | 0% | 0.7 | 41,422 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 800,000 | 800,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.45 per share. | 16 May 2025 | 172,314 | 556,338 (3%) | 1% | 0.4 | 77,472 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.56 per share. | 16 May 2025 | 147,686 | 734,024 (5%) | 1% | 0.6 | 82,246 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.50 per share. | 16 May 2025 | 30,000 | 586,338 (3%) | 0% | 0.5 | 14,994 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.71 per share. | 09 Sep 2024 | 55,579 | 299,603 (2%) | 0% | 2.7 | 150,619 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.99 per share. | 09 Sep 2024 | 51,407 | 384,024 (2%) | 0% | 3.0 | 153,707 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 09 Sep 2024 | 33,014 | 332,617 (2%) | 0% | 2.8 | 90,789 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 122,358 | 183,881 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 122,358 | 306,239 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Traversa Sergio | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.90 per share. | 29 Jan 2024 | 40,999 | 216,564 (1%) | 0% | 3.9 | 159,949 | Common Stock |
| Relmada Therapeutics Inc | Traversa Sergio | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.71 per share. | 29 Jan 2024 | 31,541 | 175,565 (1%) | 0% | 3.7 | 117,036 | Common Stock |
| Relmada Therapeutics Inc | Traversa Sergio | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 29 Jan 2024 | 27,460 | 244,024 (1%) | 0% | 4.0 | 109,752 | Common Stock |
| Relmada Therapeutics Inc | Traversa Sergio | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 183,881 | 183,881 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 527,211 | 850,728 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 131,250 | 218,750 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 87,500 | 162,500 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 62,500 | 162,500 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 31,250 | 225,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 27,123 | 6,165 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 8,231 | 3,019 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 4,131 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 323,517 | 323,517 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 16 Dec 2022 | 300,000 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 08 Dec 2022 | 55,250 | 144,024 (0%) | 0% | 2.1 | 115,804 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 30 Jun 2022 | 16,012 | 104,786 (0%) | 0% | 16 | 256,192 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 16,012 | 13,755 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 13,755 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 30 Jun 2022 | 13,755 | 102,529 (0%) | 0% | 16 | 220,080 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.01 per share. | 30 Jun 2022 | 10,698 | 88,774 (0%) | 0% | 19.0 | 203,369 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 30 Jun 2022 | 8,848 | 92,842 (0%) | 0% | 18.5 | 163,246 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.37 per share. | 30 Jun 2022 | 5,314 | 99,472 (0%) | 0% | 19.4 | 102,932 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.32 per share. | 30 Jun 2022 | 4,068 | 88,774 (0%) | 0% | 18.3 | 74,526 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 30 Jun 2022 | 839 | 101,690 (0%) | 0% | 18.5 | 15,505 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 651,821 | 1,143,994 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 492,173 | 492,173 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 10,000 | 99,211 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 09 Mar 2021 | 10,000 | 98,774 (0%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 09 Mar 2021 | 5,217 | 93,937 (0%) | 0% | 35.4 | 184,789 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.09 per share. | 09 Mar 2021 | 2,983 | 88,774 (0%) | 0% | 35.1 | 104,676 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.32 per share. | 09 Mar 2021 | 1,800 | 91,757 (0%) | 0% | 36.3 | 65,380 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 24 Feb 2021 | 10,000 | 98,774 (0%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 10,000 | 109,211 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 34.70 per share. | 24 Feb 2021 | 4,860 | 89,077 (0%) | 0% | 34.7 | 168,659 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.69 per share. | 24 Feb 2021 | 4,837 | 93,937 (0%) | 0% | 33.7 | 162,963 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.55 per share. | 24 Feb 2021 | 303 | 88,774 (0%) | 0% | 35.5 | 10,771 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.43 per share. | 11 Feb 2021 | 1,446 | 88,774 (0%) | 0% | 35.4 | 51,238 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 1,446 | 119,211 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 11 Feb 2021 | 1,446 | 90,220 (0%) | 0% | 3.2 | 4,685 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 08 Feb 2021 | 11,206 | 99,980 (0%) | 0% | 3.2 | 36,307 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 11,206 | 120,657 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.21 per share. | 08 Feb 2021 | 5,963 | 90,704 (0%) | 0% | 35.2 | 209,939 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 08 Feb 2021 | 3,313 | 96,667 (0%) | 0% | 35.0 | 116,049 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.28 per share. | 08 Feb 2021 | 1,930 | 88,774 (0%) | 0% | 35.3 | 68,097 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 13,281 | 131,863 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 02 Feb 2021 | 13,281 | 88,774 (0%) | 0% | 3.2 | 43,030 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 3,278 | 145,144 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 02 Feb 2021 | 3,278 | 92,052 (0%) | 0% | 3.2 | 10,621 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.08 per share. | 02 Feb 2021 | 3,178 | 88,874 (0%) | 0% | 35.1 | 111,470 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 02 Feb 2021 | 100 | 88,874 (0%) | 0% | 35 | 3,500 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 27 Jan 2021 | 10,000 | 85,493 (0%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 10,000 | 148,422 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.86 per share. | 27 Jan 2021 | 5,549 | 75,593 (0%) | 0% | 32.9 | 182,340 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.77 per share. | 27 Jan 2021 | 4,351 | 81,142 (0%) | 0% | 31.8 | 138,231 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.43 per share. | 27 Jan 2021 | 100 | 75,493 (0%) | 0% | 33.4 | 3,343 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 4,070 | 158,422 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 22 Jan 2021 | 4,070 | 79,563 (0%) | 0% | 3.2 | 13,187 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.44 per share. | 22 Jan 2021 | 1,736 | 77,827 (0%) | 0% | 35.4 | 61,524 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.29 per share. | 22 Jan 2021 | 1,300 | 76,093 (0%) | 0% | 35.3 | 45,877 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 22 Jan 2021 | 600 | 75,493 (0%) | 0% | 35.2 | 21,090 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.15 per share. | 22 Jan 2021 | 434 | 77,393 (0%) | 0% | 36.1 | 15,689 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 250,000 | 250,000 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 250,000 | 250,000 | - | - | Options to purchase common stock |